Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lifted its stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 82.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 399,466 shares of the company's stock after purchasing an additional 180,852 shares during the quarter. Jasper Therapeutics accounts for about 4.0% of Ally Bridge Group NY LLC's portfolio, making the stock its 9th largest position. Ally Bridge Group NY LLC owned about 2.65% of Jasper Therapeutics worth $7,514,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in JSPR. Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics in the second quarter valued at about $740,000. American Century Companies Inc. raised its holdings in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock worth $322,000 after purchasing an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter worth approximately $59,000. Rhumbline Advisers bought a new stake in Jasper Therapeutics during the 2nd quarter worth approximately $300,000. Finally, Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics in the first quarter worth $306,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on JSPR. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating for the company in a research note on Wednesday, August 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright reissued a "buy" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. JMP Securities reiterated a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, Evercore ISI reissued an "outperform" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics presently has an average rating of "Buy" and an average price target of $74.86.

Jasper Therapeutics Stock Up 2.7 %

NASDAQ:JSPR traded up $0.61 on Thursday, reaching $23.24. 185,258 shares of the company's stock traded hands, compared to its average volume of 175,451. The stock has a 50-day simple moving average of $20.27 and a 200-day simple moving average of $20.88. Jasper Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a market cap of $348.60 million, a PE ratio of -4.90 and a beta of 2.19.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.